Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential

Francesco Menzella, Mirco Lusuardi, Carla Galeone, Sofia Taddei, Nicola Facciolongo, Luigi Zucchi

Research output: Contribution to journalReview articlepeer-review

Abstract

Severe asthma is characterized by major impairment of quality of life, poor symptom control and frequent exacerbations. Inflammatory, clinical and causative factors identify different phenotypes and endotypes of asthma. In the last few years, new treatment options have allowed for targeted treatments according to the different phenotypes of the disease. To accurately select a specific treatment for each asthmatic variant, the identification of appropriate biomarkers is required. Eosinophilic asthma is a distinct phenotype characterized by thickening of the basement membrane and corticosteroid responsiveness. This review reports the latest evidence on an anti-IL-5 monoclonal antibody, mepolizumab, a new and promising biological agent recently approved by the FDA specifically for the treatment of severe eosinophilic refractory asthma.

Original languageEnglish
Pages (from-to)260-277
Number of pages18
JournalTherapeutic Advances in Chronic Disease
Volume7
Issue number6
DOIs
Publication statusPublished - Nov 1 2016

Keywords

  • asthma
  • costs
  • effectiveness
  • IL-5
  • mepolizumab
  • phenotype

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Fingerprint

Dive into the research topics of 'Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential'. Together they form a unique fingerprint.

Cite this